Meeting
2014 ASCO Annual Meeting
Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL).
Authors
Anastasios Stathis
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Anastasios Stathis , Kami J. Maddocks , Ian Flinn , Alex Mejia , Maria Lia Palomba , Sybil Zildjian , Mary Murphy , Jutta Deckert , Rodrigo Ruiz-Soto , Arnold Freedman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
01534715
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8526)
DOI
10.1200/jco.2014.32.15_suppl.8526
Abstract #
8526
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
First Author: Yang Xie
Poster
2023 ASCO Annual Meeting
A phase 1 study of AT101, a novel anti-CD19 CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
First Author: Dok Hyun Yoon
Poster
2016 ASCO Annual Meeting
A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (BâNHL).
First Author: Ki Y. Chung
Poster
2013 ASCO Annual Meeting
Phase I study of a novel humanized anti-CD20 antibody, BM-ca, in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab.
First Author: Kensei Tobinai